EXPERIMENTAL
The IR spectra of nujol suspensions of compounds were taken on a Perkin-Elmer 2000 Fourier
1
spectrometer, and the H NMR spectra on a Unity 400+ (400 MHz) spectrometer, internal standard was TMS.
The mass spectra were recorded on a Kratos MS-30 instrument with direct insertion of sample into the ion
source (ionization energy 70 eV). A check on the progress of reactions and the homogeneity of the synthesized
compounds was effected by TLC on Silufol UV-254 plates in the solvent system benzene–acetone, 10:1, the
developer was a solution of KMnO4 (1 g) in H2SO4 (4 ml) and H2O (96 ml).
2-Alkylbenzimidazoles 2a-e (General Method). A mixture of compound 1 (1.38 g, 10 mmol), the
appropriate carboxylic acid (60 mmol), iron powder (1.68 g, 30 mmol) and 32% HCl (10 ml) was heated to
70oC. After the end of the vigorous evolution of hydrogen the mixture was maintained at the same temperature
for 1 h, and then at 90-100oC for 2 h. The reaction mixture was cooled, 20% NaOH solution was added to pH
9-10, the precipitated solid was filtered off, and washed with water until neutral reaction. Alcohol (20 ml) was
added to the washed solid, the mixture was boiled for 1 h, and filtered without cooling. Alcohol (~10 ml) was
distilled from the filtrate, the residue was diluted with three volumes of water, the resulting product 2 was
filtered off, and recrystallized from the appropriate solvent. The melting points of the synthesized compounds
2a-e, and of samples of them obtained by cyclization of o-phenylenediamine with carboxylic acids [10],
coincided.
2-Alkyl-1-arylsulfonylbenzimidazoles 3a-e to 8a-e (General Method). A solution of compound 2
(10 mmol) and triethylamine (1.11 g, 11 mmol) in acetone (30 ml) was added dropwise to a solution of the
appropriate arene sulfonyl chloride (11 mmol) in acetone (20 ml). The reaction mixture was stirred at room
temperature for 4 h, the acetone was then distilled, and water (50 ml) was added to the residue. The solid
product obtained of 3a-e to 8a-e was filtered off and recrystallized from the appropriate solvent.
REFERENCES
1.
2.
D. A. Dushamov, N. S. Mukhamedov, N. A. Aliev, Kh. M. Bobokulov, M. G. Levkovich, and
N. D. Abdullaev, Khim. Geterotsikl. Soedin., 503 (2002). [Chem. Heterocycl. Comp., 38, 438 (2002)].
M. Negwer and H. G. Sharnow, Organic-Chemical Drugs and Their Synonyms, 8 Extensiv. Enlarg. Ed.,
Wiley-VCH Verlag, Weinhein (2001).
3.
4.
V. Klimesova, J. Koi, K. Waisser, and J. Kaustova, Farmaco, 57, 259 (2002).
J. Koci, V. Klimesova, K. Waisser, J. Kaustova, H. M. Danse, and U. Möllman, Bioorg. Med. Chem.
Lett., 12, 3275 (2002).
5.
6.
7.
8.
M. Guardiola-Diaz, L. A. Foster, D. Mushrush, and D. N. Vaz, Biochem. Pharmacol., 61, 1463 (2001).
O. Geban, H. Ertepinar, and S. Oezden, Pharmazie, 51, 34 (1996).
A. A. Umarov, N. P. Loi, Ch. Sh. Kadyrov, and A. T. Ayupova, Agrokhimiya, No. 7, 123 (1973).
A. A. Umarov, Benzimidazoles, Their Regulating Properties and Functions, Fan, Tashkent (1990),
p. 132.
9.
H. Foks, D. Pancechowska-Ksepko, W. Kuzmierkewicz-Kopec, Z. Zwolska, E. Augustynowicz-Kopec,
and M. Janowiec, Khim. Geterotsikl. Soedin., 697 (2006). [Chem. Heterocycl. Comp., 42, 611 (2006)].
A. T. Ayupova, Diss. Cand. Chem. Sci., Tashkent (1973).
10.
946